PatternsRadar
Sign in

BROOKSBrooks Laboratories Limited

NSE
Full chart
59.66INR+5.42 (+9.99%)Close · 6 Oct 2026
13 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹176 CrMarket cap
13.3P/E (TTM)
84.1%Delivery

Filings & corporate actions

61 results filed
CSV
Next results · Q2 FY27
Expected 9 Nov 2026 – 15 Nov 2026
Estimate: filed 40–46 days after quarter end, last 5 times
2026
  • 13 AugresultsResults · Q1 FY27 · consolidated and standalone-4.9%NSE
  • 9 JulshareholdingShareholding · 30 Jun 2026+1.3%NSE
  • 29 MayresultsResults · Q4 FY26 · consolidated and standalone+5.0%NSE
  • 14 AprshareholdingShareholding · 31 Mar 2026+0.6%NSE
  • 6 FebresultsResults · Q3 FY26 · consolidated and standalone+13.6%NSE
  • 9 JanshareholdingShareholding · 31 Dec 2025-0.7%NSE

Reaction to results · all yearsrose on day 0 in 28 of 60 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY2713 Aug 2026-4.9%-8.5%+0.1%1.6×
Q4 FY2629 May 2026+5.0%+2.1%+5.5%1.7×
Q3 FY266 Feb 2026+13.6%+22.0%+2.5%21.5×
Q2 FY2614 Nov 2025-3.9%-10.0%-10.2%1.1×
Q1 FY2613 Aug 2025-3.5%-7.6%+0.8%2.2×
Q4 FY2528 May 2025+5.0%+6.5%+15.4%1.9×
Q3 FY2513 Feb 2025-6.1%-13.5%-28.8%2.2×
Q2 FY259 Nov 2024-0.3%+1.3%+3.8%0.2×
Q1 FY2515 Aug 2024+2.2%+40.1%+60.6%0.5×
Q4 FY2418 May 2024-4.0%-5.7%-3.4%5.1×
Q3 FY2431 Jan 2024-3.5%-10.0%-19.9%0.7×
Q2 FY249 Nov 2023+2.0%+8.2%+1.6%1.3×
Q1 FY2410 Aug 2023+5.0%+7.1%+17.8%1.2×
Q4 FY2330 May 2023+0.9%+5.5%+26.4%1.1×
Q3 FY2315 Feb 2023+0.8%-4.9%-35.1%0.2×
Q2 FY2315 Nov 2022+1.2%+2.3%+9.4%0.6×
Q1 FY2310 Aug 2022+0.1%+21.7%+59.2%1.3×
Q4 FY2231 May 2022+1.4%+7.1%+4.9%0.4×
Q3 FY2214 Feb 2022+3.6%-9.2%-1.6%0.6×
Q2 FY2212 Nov 2021-5.0%-10.9%-4.1%1.3×
Q1 FY2214 Aug 2021-9.7%-7.7%+18.8%2.5×
Q4 FY211 Jul 2021-1.9%-5.5%+0.1%1.4×
Q3 FY2112 Feb 2021-4.9%+0.9%-9.0%1.9×
Q2 FY2113 Nov 2020+8.3%-0.8%+12.6%2.6×
Q1 FY2116 Sept 2020+4.8%+32.6%+45.7%3.5×
Q4 FY2031 Jul 2020+4.5%-1.4%+13.7%0.6×
Q3 FY2015 Feb 2020-11.7%-28.0%-43.3%1.1×
Q2 FY2014 Nov 2019-2.5%-4.9%-20.4%0.7×
Q1 FY2014 Aug 2019-0.9%-16.1%-2.0%0.4×
Q4 FY1930 May 2019-0.3%-2.1%-14.8%1.3×
Q3 FY1926 Feb 2019+3.4%-0.6%-8.5%13.0×
Q2 FY1926 Nov 2018-2.0%-4.8%+8.8%0.2×
Q1 FY1931 Aug 2018+9.4%+6.3%-22.5%21.8×
Q4 FY1826 Jun 2018-3.3%-6.3%-11.8%0.6×
Q3 FY1812 Mar 2018+1.1%-1.9%+5.1%0.4×
Q2 FY1826 Dec 2017-0.6%+1.9%+2.7%0.6×
Q1 FY1821 Sept 2017-0.6%-7.5%-6.1%1.0×
Q4 FY1718 Jun 2017+0.3%-5.1%-5.3%0.5×
Q3 FY1721 Feb 2017+1.0%-0.2%-4.6%0.4×
Q2 FY1718 Nov 2016-5.0%+5.5%+9.0%0.2×
Q1 FY1713 Aug 2016-10.4%-3.6%+7.2%0.7×
Q4 FY1628 May 2016+1.6%+1.7%+0.8%1.2×
Q3 FY1613 Feb 2016+9.9%+6.6%+17.9%0.4×
Q2 FY167 Nov 2015+0.3%+7.8%+21.2%1.6×
Q1 FY1616 Aug 2015+5.0%+2.2%-27.1%0.5×
Q4 FY154 Jun 2015-1.5%+10.3%+33.7%0.6×
Q3 FY1519 Feb 2015-0.6%-6.8%-5.1%0.6×
Q2 FY1520 Nov 2014+8.1%-3.8%-11.2%5.4×
Q1 FY1520 Aug 2014-0.6%-8.5%-0.8%0.2×
Q4 FY1429 May 2014-2.0%+2.0%+26.5%0.9×
Q3 FY1420 Feb 2014-3.1%-2.3%-0.8%0.9×
Q2 FY1425 Nov 2013-2.6%-0.3%+9.8%0.2×
Q1 FY1412 Aug 2013-4.4%-6.6%-2.5%5.6×
Q4 FY1327 Jun 20130.0%+1.3%+0.6%0.3×
Q3 FY1314 Feb 2013-0.8%-4.4%+6.9%1.1×
Q2 FY1310 Nov 2012+9.4%-3.7%-3.3%3.0×
Q1 FY1314 Aug 2012+0.6%-7.2%-1.4%0.3×
Q4 FY1212 Jun 2012-1.0%+1.0%+32.3%1.0×
Q3 FY1217 Feb 2012-4.8%-26.2%-33.7%0.2×
Q2 FY129 Nov 2011+6.7%-10.2%-25.7%2.8×
Average+0.1%-0.9%+2.0%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY-10.0%
Profit YoY-118.6%
Interest cost YoY-36.7%
Revenue QoQ+13.6%
Profit QoQ-217.3%
CAGR2Y3Y4Y5Y6Y7Y
Revenue+0.9%+10.5%-0.7%-0.8%——
Profit——————

Key data

CSV
Open56.34
Day range54.30 – 59.66
52-week range36.30 – 142.27
From 52w high-58.1%
RSI (14)48.8
ATR (14)3.50
Volume58.7K
Avg volume (20D)43.2K
Rel volume1.36×
Volatility (1Y)66.4%
Turnover₹35.0L
SMA 50 / 20061.48 / 65.20

Delivery percentage

Latest · 6 Oct 202684.1%
20-day avg67.3%
1-year avg74.9%
Percentile (own history)56th
Range16.6–100.0%
Sessions1,725

Over the last 20 sessions BROOKS settled 67.3% of its traded quantity, which is unusually high for an NSE equity. Its one-year average is 74.9%, so recent sessions are running 7.6 points lower than usual. The latest session ranks higher than 56% of the 1,725 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+9.99%+5.50%-7.00%-18.31%+11.76%-55.97%

Valuation

CSV
Market cap₹176 Cr
P/E (TTM)13.3
EPS (TTM)4.49
Shares outstanding2.95Cr
Listed5 Sept 2011

Ownership

CSV
Promoter52.62%
Promoter Δ QoQ0.00 pp
Public47.38%
FII0.00%
DII10.38%
Pledged0.00%

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)23.516.620.223.0
YoY chg+12.8%-19.2%-13.3%-10.0%
Net profit (₹ Cr)8.05.51.5(1.8)
YoY chg———-118.6%
Net margin34.0%33.2%7.5%-7.8%
EPS2.711.870.52-0.61

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 52.62% · public 47.38%
30 Sept 2021: promoter 66.41%31 Dec 2021: promoter 66.41%31 Mar 2022: promoter 66.41%30 Jun 2022: promoter 66.41%30 Sept 2022: promoter 66.41%31 Dec 2022: promoter 66.41%31 Mar 2023: promoter 66.41%30 Jun 2023: promoter 66.41%28 Aug 2023: promoter 63.59%30 Sept 2023: promoter 63.59%31 Dec 2023: promoter 63.59%31 Mar 2024: promoter 63.59%30 Jun 2024: promoter 63.59%30 Sept 2024: promoter 63.59%31 Dec 2024: promoter 59.06%29 Jan 2025: promoter 52.62%31 Mar 2025: promoter 52.62%30 Jun 2025: promoter 52.62%30 Sept 2025: promoter 52.62%31 Dec 2025: promoter 52.62%31 Mar 2026: promoter 52.62%30 Jun 2026: promoter 52.62%
2021-092026-06
  • Promoter
  • Public and others
Promoter
52.62%
Public
47.38%
Promoter change
0.00 pp
Filed
9 Jul 2026
FII
0.00%
DII
10.38%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27
Revenue from operations24.321.717.717.920.820.523.325.523.516.620.223.0
Other income0.10.20.70.10.20.00.60.20.40.10.40.2
Total income24.421.918.418.021.020.523.925.723.816.720.623.1
Total expenses23.221.318.118.220.019.622.423.121.616.420.021.7
└ Finance costs0.20.20.30.20.30.30.30.30.30.20.10.2
└ Depreciation0.40.40.50.40.40.40.40.40.40.40.40.4
Profit before tax1.20.60.3(0.2)1.00.91.52.72.20.30.61.4
Tax expense0.00.00.00.00.00.00.20.00.00.00.00.0
Net profit(1.6)(3.9)(9.6)(2.4)(4.0)(2.1)(1.5)9.68.05.51.5(1.8)
EPS-0.64-1.51-3.77-0.94-1.51-0.82-0.543.252.711.870.52-0.61
Net margin-6.73%-17.84%-54.20%-13.46%-19.06%-10.39%-6.25%37.57%34.02%33.19%7.54%-7.78%
PBT margin4.85%2.78%1.71%-1.18%4.60%4.56%6.49%10.39%9.54%1.83%3.04%6.18%
Tax rate0.00%4.29%0.00%—0.00%0.00%11.60%0.00%0.00%0.00%0.00%0.00%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 13 Aug 2026.

BROOKS at a glance

  • BROOKS closed at ₹59.66 on 6 Oct 2026, +9.99% on the day, -56.0% over one year, 58.1% below its 52-week high of ₹142.27.
  • Delivery was 84.1% of traded quantity on 6 Oct 2026, the 56th percentile of its own 1,725 sessions with a reading (20-session average 67.3%, 1-year average 74.9%).
  • Market capitalisation is ₹176 crore at a trailing P/E of 13.3 (trailing EPS ₹4.49).
  • Q1 FY27 results (consolidated, filed 13 Aug 2026): revenue ₹23 crore (-10.0% year on year), net profit ₹-2 crore (-118.6%); the price moved -4.9% on the first session after.
  • Promoters held 52.62% at 30 Jun 2026, unchanged on the previous filing.
  • Q2 FY27 results are expected between 9 Nov 2026 and 15 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE650L01011
SeriesEQ
Listed5 Sept 2011
History from5 Sept 2011
Sessions3,735

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE